SINGAPORE, July 14, 2025 — Gero, a Singapore-based biotechnology company utilizing AI to develop treatments for age-related illnesses, has announced the appointment of Dr. Brian Kennedy, a renowned expert in longevity, to its Board of Directors.
Dr. Kennedy is currently a Distinguished Professor in the Departments of Biochemistry and Physiology at the National University of Singapore’s Yong Loo Lin School of Medicine (NUS). He also leads the Healthy Longevity Translational Research Programme, the Bia-Echo Asia Centre for Reproductive Longevity and Equality, and the Centre for Healthy Longevity at the National University Health System. These programs are focused on validating interventions that can extend human healthspan, which refers to the years of life spent free from disease and in good functional health.
“We are delighted to welcome Brian to our Board,” stated Dr. Peter Fedichev, CEO & Co-Founder of Gero. “His extensive experience in the biology of aging, combined with his success in translating research into practical clinical and commercial applications, perfectly complements Gero’s goal of using AI and human data to identify and target the fundamental causes of aging. Brian’s insights will be invaluable as we continue to expand our platform and progress our programs toward clinical trials.”
Previously, Dr. Kennedy was President and CEO of the Buck Institute for Research on Aging. He also held a faculty position in the Department of Biochemistry at the University of Washington, where he still holds an adjunct appointment. He has also been a Visiting Professor at the Aging Research Institute at Guangdong Medical College and has maintained active involvement in the biotech industry, holding leadership and advisory positions in numerous companies.
“I have long been convinced that scientific understanding of the aging process needs to be combined with ambitious translational efforts,” Dr. Kennedy commented. “Gero’s approach, which utilizes AI, human data, and physics-based models, offers a highly promising route to developing innovative therapies that can extend human healthspan. I am eager to support their vision and help guide their progress.”
Dr. Kennedy also served as Co-Editor-in-Chief of Aging Cell, a leading journal in the field. He received his Ph.D. from MIT under the guidance of Dr. Leonard Guarente, where he co-authored a seminal paper linking Sirtuins to aging.
About Gero PTE. LTD.
Gero PTE. LTD., headquartered in Singapore, is a preclinical-stage AI-driven biotechnology company focused on developing therapeutics for age-related diseases with the goal of extending healthy human lifespan. Gero’s technology platform is based on physics-based machine learning and human data, enabling the discovery of therapeutic targets and the development of therapies that address age-related diseases and target the underlying causes of aging. More information can be found at: .
Contact:
Investors
Gero
Alex Kadet
Chief Business Officer
Media
Kimberly Ha
KKH Advisors
“`
